Fidelity Investments’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Fidelity Investments’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,000	Closed	-$1K	–	5678
2022 Q3	$1K	Sell	4,000 -50	-1%	-$20	﹤0.01%	4791
2022 Q2	$1K	Sell	4,050 -313,450	-99%	-$159K	﹤0.01%	4857
2022 Q1	$216K	Buy	317,500 +1,300	+0.4%	+$1.43K	﹤0.01%	3236
2021 Q4	$730K	Buy	316,200 +700	+0.2%	+$2.37K	﹤0.01%	2726
2021 Q3	$1.45M	Sell	315,500 -184,500	-37%	-$811K	﹤0.01%	2629
2021 Q2	$2.22M	Hold	500,000	–	–	﹤0.01%	2531
2021 Q1	$3.64M	Hold	500,000	–	–	﹤0.01%	2341
2020 Q4	$3.81M	Buy	+500,000	New	+$3.35M	﹤0.01%	2244

Fidelity Investments's LOGC Position: Q4 2022 in Review

Fidelity Investments sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 4,000 shares — an estimated $1K sold.

Fidelity Investments first reported a position in LOGC in Q4 2020 and held it in 8 quarters. The position peaked at $3.81M in Q4 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Fidelity Investments reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Fidelity Investments sold 4,000 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
Fidelity Investments first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Fidelity Investments's LogicBio Therapeutics, Inc. Common Stock position peaked at $3.81M in Q4 2020.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Fidelity Investments's 13F filing for Q4 2022, filed 13 Feb 2023.